Table 2.
Baseline Demographics and Characteristics
| ABC/3TC/ZDV (N = 139) | ATV+3TC/ZDV (N = 140) | |
| Median Age, years (range) | 38 (19–65) | 36 (18–68) |
| Female Gender, n (%) | 30 (22%) | 28 (20%) |
| Race, n (%) | ||
| White | 65 (47%) | 58 (41%) |
| Black | 44 (32%) | 49 (35%) |
| American Hispanic | 26 (19%) | 29 (21%) |
| Other | 4 (3%) | 4 (3%) |
| CDC Class C, n (%) | 6 (4%) | 5 (4%) |
| Median HIV-1 RNA, log10 copies/mL (range) | 4.48 (2.3–5.5) | 4.64 (2.6–5.6) |
| HIV-1 RNA ≥ 100,000 copies/mL, n (%) | 24 (17%) | 25 (18%) |
| Median CD4+ cell count, (cells/mm3) (range) | 274 (103–889) | 262 (50–749) |
| CD4+ cell count ≥ 200 cells/mm3, n (%) | 105 (76%) | 97 (69%) |
| Hepatitis B positive, n (%) | 2 (1%) | 6 (4%) |
| Hepatitis C positive, n (%) | 9 (6%) | 10 (7%) |
| Hepatitis & B positive, n (%) | 0 | 1 (<1%) |
Abbreviations: abacavir sulfate (ABC), atazanavir (ATV), lamivudine (3TC), zidovudine (ZDV)